Abemaciclib plus Endocrine Therapy Offers Invasive Disease–Free Survival Benefit in Patients with High-Risk, HR-Positive, Early-Stage Breast Cancer

TOP - May 2021 Vol 14, No 3 - Breast Cancer

The addition of the cyclin-dependent kinase (CDK)4/6 inhibitor abemaciclib (Verzenio) to standard endocrine therapy reduced the risk for invasive disease recurrence or death compared with endocrine therapy alone by almost 30% in patients with high-risk, hormone receptor (HR)-positive, human epidermal growth receptor 2 (HER2)-negative, early-stage breast cancer. These results come from the primary analysis of the phase 3 monarchE clinical trial that was presented at the virtual 2020 San Antonio Breast Cancer Symposium.

Although many patients with HR-positive early-stage breast cancer will not have disease recurrence with endocrine therapy alone, “Approximately 20% may experience disease recurrence in the first 10 years, often in the form of incurable metastatic breast cancer,” said Priya Rastogi, MD, Associate Professor, University of Pittsburgh School of Medicine, PA, who presented the new results.

At a median follow-up of 19 months, after 385 events had occurred, the invasive disease–free survival (IDFS) benefit was statistically significant and clinically meaningful (P = .0009). The 2-year IDFS rates were 92.3% with abemaciclib plus endocrine therapy versus 89.3% with endocrine therapy alone, translating to a 28.7% reduction in risk and an absolute difference of 3% favoring abemaciclib.

“Abemaciclib combined with standard endocrine therapy continued to demonstrate a reduction in the risk of developing IDFS and distant relapse–free survival events for patients with HR-positive, HER2-negative, high-risk early breast cancer, and resulted in a statistically significant improvement in IDFS in patients with high Ki-67 tumors,” said Dr Rastogi.

“Abemaciclib in combination with endocrine therapy is the first CDK4/6 inhibitor to demonstrate efficacy and tolerability” for this patient population, she added.

Abemaciclib is currently approved for the treatment of patients with HR-positive, HER2-negative advanced or metastatic breast cancer, in combination with a nonsteroidal aromatase inhibitor, fulvestrant, or as monotherapy.

Study Details

The 5637 patients enrolled in the monarchE trial were divided into 2 cohorts. Cohort 1 was based on clinicopathological risk factors (ie, ≥4 positive axillary lymph nodes or 1-3 axillary lymph nodes and at least a grade 3 histology or a tumor size ≥5 cm); cohort 2 was based on Ki-67 status (ie, 1-3 axillary lymph nodes, a centrally tested Ki-67 index of ≥20%, no grade 3 histology, and a tumor size <5 cm).

Patients were randomized in a 1:1 ratio to standard endocrine therapy alone for 5 to 10 years, as clinically indicated, or to endocrine therapy plus abemaciclib at 150 mg twice daily for up to 2 years. Stratification factors were previous chemotherapy, menopausal status, and geographic region.

The study’s primary end point was IDFS; the secondary outcome measures included IDFS in the Ki-67–high (≥20%) population (N = 2498), distant relapse–free survival, overall survival, safety, patient-reported outcomes, and pharmacokinetics.

Previously presented data at the 2020 European Society for Medical Oncology meeting showed that at a median follow-up of 15.5 months, abemaciclib reduced the risk for invasive disease by 25.3% versus endocrine therapy alone (2-sided P = .0096). The 2-year IDFS rates were 92.2% in the abemaciclib arm versus 88.7% in the endocrine therapy–alone arm, for an absolute improvement of 3.5%.

At the time of the analysis presented by Dr Rastogi, 1437 (25.5%) patients had completed the 2-year treatment period.

Ki-67 was evaluated in all patients in cohort 1 and cohort 2 who had suitable untreated breast tissue. In the primary analysis, in the Ki-67–high population (N = 2498), the risk for an IDFS event was reduced by 30.9% with abemaciclib compared with endocrine therapy alone (2-sided P = .0111), which was clinically meaningful. The 2-year IDFS rates were 91.6% with abemaciclib and 87.1% with endocrine therapy alone, for an absolute difference of 4.5%.

In the intention-to-treat analysis, abemaciclib reduced the risk for distant relapse–free survival by 31.3% versus endocrine therapy alone (P = .0009), which was deemed clinically meaningful. The 2-year survival without distant relapse rates were 93.8% and 90.8%, a 3% absolute difference favoring abemaciclib.

The safety profile of abemaciclib was consistent with previous reports. Most treatment discontinuations were because of adverse effects and occurred within the first 5 months of abemaciclib treatment. In addition, most patients who required dose interruptions or reductions were able to continue with abemaciclib therapy.

The planned follow-up for the monarchE study is 10 years.

Cautiously Optimistic

Commenting on the results of the additional 4 months of follow-up in this study, C. Kent Osborne, MD, Founding Director, Dan L. Duncan Comprehensive Cancer Center, and Dudley and Tina Sharp Chair for Cancer Research, Baylor College of Medicine, Houston, TX, said, “I think these results are encouraging, especially in the subgroup of tumors with high proliferation.”

However, he cautioned that this follow-up period is short for estrogen receptor–positive breast cancer, which can recur years later. And, he added, “This class of inhibitors is largely cytostatic rather than cytocidal, meaning that it blocks cell proliferation rather than killing the cells. An important question remains: will the invasive disease–free survival curves come together when the drug is stopped? With these caveats in mind, this is still a very important trial,” Dr Osborne concluded.

Related Items
Multicancer Early Detection Blood Test May Change Cancer Screening Paradigms
Patricia Stewart
TOP - November 2022 Vol 15, No 6 published on November 9, 2022 in ESMO
Factors Associated with Greater Risk for Abemaciclib Discontinuation in Patients with Early-Stage Breast Cancer
William King
TOP - November 2022 Vol 15, No 6 published on November 9, 2022 in Breast Cancer
Determination Trial Confirms Importance of Individualizing Therapy for Newly Diagnosed Multiple Myeloma
Patricia Stewart
TOP - November 2022 Vol 15, No 6 published on November 9, 2022 in Multiple Myeloma
Researchers Discover How Air Pollution May Trigger Lung Cancer in Never-Smokers
Patricia Stewart
TOP - November 2022 Vol 15, No 6 published on November 9, 2022 in ESMO
Promising New Approach to Treating Patients with Desmoid Tumors
Patricia Stewart
TOP - November 2022 Vol 15, No 6 published on November 9, 2022 in ESMO
Radiation Therapy May Be Omitted for Some Older Women with Luminal A Breast Cancer
Patricia Stewart
TOP - November 2022 Vol 15, No 6 published on November 9, 2022 in Breast Cancer
Trastuzumab Deruxtecan Represents New Standard of Care for Patients with HER2-Low Metastatic Breast Cancer
William King
TOP - September 2022 Vol 15, No 5 published on September 15, 2022 in Breast Cancer
Niraparib plus Abiraterone Combination Extends PFS in Men with CRPC and HRR Gene Mutations
Patricia Stewart
TOP - September 2022 Vol 15, No 5 published on September 15, 2022 in Prostate Cancer
Sotorasib Achieves Durable Responses in Patients with Metastatic NSCLC and KRAS Mutation
Patricia Stewart
TOP - September 2022 Vol 15, No 5 published on September 15, 2022 in Lung Cancer
Black Patients with Cancer and COVID-19 More Likely to Have Treatment Disruptions Than White Patients
Patricia Stewart
TOP - September 2022 Vol 15, No 5 published on September 15, 2022 in COVID-19 & Cancer
Last modified: July 22, 2021